Unbiased approaches to biomarker discovery in neurodegenerative diseases

Neuron

Volumn 84, Issue 3, 2014, Pages 594-607

  Chen Plotkin, Alice S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; DNA; DOPAMINE; DOPAMINE TRANSPORTER; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; MICRORNA; PITTSBURGH COMPOUND B; RNA; TAU PROTEIN; URATE; URIC ACID;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DIFFUSION TENSOR IMAGING; DOPAMINERGIC SYSTEM; FRACTIONAL ANISOTROPY; FRONTOTEMPORAL DEMENTIA; GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SRRM2 GENE; SUBSTANTIA NIGRA; TANDEM MASS SPECTROMETRY; ANIMAL; BRAIN; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ANIMALS; BIOMARKERS; BRAIN; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84912088714     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.10.031     Document Type: Review

References (166)

1. Adler C.H., Dugger B.N., Hinni M.L., Lott D.G., Driver-Dunckley E., Hidalgo J., Henry-Watson J., Serrano G., Sue L.I., Nagel T., et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 2014, 82:858-864.
2. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
3. Alves G., Brønnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., Kurz M.W., Andreasson U., Tysnes O.B., Larsen J.P., Mulugeta E. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J.Neurol. Neurosurg. Psychiatry 2010, 81:1080-1086.
4. Alzheimer's Disease Neuroimaging Initiative (2013). Alzheimer's Disease Neuroimaging Initiative. http://www.adni-info.org.
5. Baird G.S., Nelson S.K., Keeney T.R., Stewart A., Williams S., Kraemer S., Peskind E.R., Montine T.J. Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am. J. Pathol. 2012, 180:446-456.
6. Bajaj N., Hauser R.A., Grachev I.D. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J.Neurol. Neurosurg. Psychiatry 2013, 84:1288-1295.
7. Bartels C.L., Tsongalis G.J. MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 2009, 55:623-631.
8. Beach T.G., Adler C.H., Sue L.I., Vedders L., Lue L., White Iii C.L., Akiyama H., Caviness J.N., Shill H.A., Sabbagh M.N., Walker D.G. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119:689-702. Arizona Parkinson's Disease Consortium.
9. Berardelli A., Wenning G.K., Antonini A., Berg D., Bloem B.R., Bonifati V., Brooks D., Burn D.J., Colosimo C., Fanciulli A., et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur. J. Neurol. 2013, 20:16-34.
10. Berg D., Postuma R.B., Bloem B., Chan P., Dubois B., Gasser T., Goetz C.G., Halliday G.M., Hardy J., Lang A.E., et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord. 2014, 29:454-462.
11. BioFIND Clinical Study (2014). BioFIND Clinical Study. https://www.michaeljfox.org/page.html?biofind-clinical-study.
12. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95. Biomarkers Definitions Working Group.
13. Björkqvist M., Ohlsson M., Minthon L., Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS ONE 2012, 7:e29868.
14. Bogdanov M., Matson W.R., Wang L., Matson T., Saunders-Pullman R., Bressman S.S., Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008, 131:389-396.
15. Boja E.S., Rodriguez H. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics 2012, 12:1093-1110.
16. Booij J., Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:424-438.
17. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 2000, 287:65-67.
18. Braak H., Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008, 70:1916-1925.
19. Brindle J.T., Antti H., Holmes E., Tranter G., Nicholson J.K., Bethell H.W., Clarke S., Schofield P.M., McKilligin E., Mosedale D.E., Grainger D.J. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabolomics. Nat. Med. 2002, 8:1439-1444.
20. Brooks D.J. Imaging approaches to Parkinson disease. J.Nucl. Med. 2010, 51:596-609.
21. Buter T.C., van den Hout A., Matthews F.E., Larsen J.P., Brayne C., Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008, 70:1017-1022.
22. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
23. Carlson J.J., Roth J.A. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2013, 141:13-22.
24. Chahine L.M., Stern M.B., Chen-Plotkin A. Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat. Disord. 2014, 20(Suppl 1):S99-S103.
25. Chen-Plotkin A.S., Hu W.T., Siderowf A., Weintraub D., Goldmann Gross R., Hurtig H.I., Xie S.X., Arnold S.E., Grossman M., Clark C.M., et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann. Neurol. 2011, 69:655-663.
26. Compta Y., Martí M.J., Ibarretxe-Bilbao N., Junqué C., Valldeoriola F., Muñoz E., Ezquerra M., Ríos J., Tolosa E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 2009, 24:2203-2210.
27. Cummings J.L., Henchcliffe C., Schaier S., Simuni T., Waxman A., Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011, 134:3146-3166.
28. Davis J.W., Grandinetti A., Waslien C.I., Ross G.W., White L.R., Morens D.M. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am. J. Epidemiol. 1996, 144:480-484.
29. de Lau L.M., Koudstaal P.J., Hofman A., Breteler M.M. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 2005, 58:797-800.
30. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. USA 2009, 106:13010-13015.
31. Diao H., Li X., Hu S., Liu Y. Gene expression profiling combined with bioinformatics analysis identify biomarkers for Parkinson disease. PLoS ONE 2012, 7:e52319.
32. Dickson D.W., Braak H., Duda J.E., Duyckaerts C., Gasser T., Halliday G.M., Hardy J., Leverenz J.B., Del Tredici K., Wszolek Z.K., Litvan I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009, 8:1150-1157.
33. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
34. Dorsey E.R., George B.P., Leff B., Willis A.W. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology 2013, 80:1989-1996.
35. Druschky A., Hilz M.J., Platsch G., Radespiel-Tröger M., Druschky K., Kuwert T., Neundörfer B. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J.Neurol. Sci. 2000, 175:3-12.
36. Duncan M.W., Hunsucker S.W. Proteomics as a tool for clinically relevant biomarker discovery and validation. Exp. Biol. Med. (Maywood) 2005, 230:808-817.
37. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
38. Ellington A.D., Szostak J.W. Invitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
39. Ellington A.A., Kullo I.J., Bailey K.R., Klee G.G. Antibody-based protein multiplex platforms: technical and operational challenges. Clin. Chem. 2010, 56:186-193.
40. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/β-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
41. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
42. Foulds P.G., Yokota O., Thurston A., Davidson Y., Ahmed Z., Holton J., Thompson J.C., Akiyama H., Arai T., Hasegawa M., et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol. Dis. 2012, 45:188-195.
43. Goldstein D.B. Common genetic variation and human traits. N.Engl. J. Med. 2009, 360:1696-1698.
44. Goodacre R., Vaidyanathan S., Dunn W.B., Harrigan G.G., Kell D.B. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 2004, 22:245-252.
45. Greenberg B.D., Carrillo M.C., Ryan J.M., Gold M., Gallagher K., Grundman M., Berman R.M., Ashwood T., Siemers E.R. Improving Alzheimer's disease phase II clinical trials. Alzheimers Dement. 2013, 9:39-49.
46. Gurbel P.A., Kreutz R.P., Bliden K.P., DiChiara J., Tantry U.S. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am. Heart J. 2008, 155:56-61.
47. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
48. Hajee M.E., March W.F., Lazzaro D.R., Wolintz A.H., Shrier E.M., Glazman S., Bodis-Wollner I.G. Inner retinal layer thinning in Parkinson disease. Arch. Ophthalmol. 2009, 127:737-741.
49. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9:560-574.
50. Han X., Gross R.W. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 2005, 24:367-412.
51. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 2008, 23:837-844.
52. Henchcliffe C., Dodel R., Beal M.F. Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Prog. Neurobiol. 2011, 95:601-613.
53. Holmes E., Loo R.L., Stamler J., Bictash M., Yap I.K., Chan Q., Ebbels T., De Iorio M., Brown I.J., Veselkov K.A., et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453:396-400.
54. Holmes E., Wilson I.D., Nicholson J.K. Metabolic phenotyping in health and disease. Cell 2008, 134:714-717.
55. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Leverenz J.B., Baird G., et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
56. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J.Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
57. Hughes A.J., Daniel S.E., Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001, 57:1497-1499.
58. Hutchinson M., Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. AJNR Am. J. Neuroradiol. 2000, 21:697-701.
59. Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary 2008, Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders, National Academies Press, Washington, D.C.
60. Irwin D.J., Lee V.M., Trojanowski J.Q. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 2013, 14:626-636.
61. Jack C.R., Holtzman D.M. Biomarker modeling of Alzheimer's disease. Neuron 2013, 80:1347-1358.
62. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Thies B., Phelps C.H. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:257-262.
63. Kang J.H., Vanderstichele H., Trojanowski J.Q., Shaw L.M. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Methods 2012, 56:484-493.
64. Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S., Waligórska T., Taylor P., Pan S., Frasier M., et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013, 70:1277-1287. Parkinson's Progression Markers Initiative.
65. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C., Henning A.K., SanGiovanni J.P., Mane S.M., Mayne S.T., et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
66. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
67. Kowal S.L., Dall T.M., Chakrabarti R., Storm M.V., Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 2013, 28:311-318.
68. Kozauer N., Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N.Engl. J. Med. 2013, 368:1169-1171.
69. la Marca G. Mass spectrometry in clinical chemistry: the case of newborn screening. J.Pharm. Biomed. Anal. 2014, Published online April 28, 2014. 10.1016/j.jpba.2014.03.047.
70. Lebouvier T., Neunlist M., Bruley des Varannes S., Coron E., Drouard A., N'Guyen J.M., Chaumette T., Tasselli M., Paillusson S., Flamand M., et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010, 5:e12728.
71. Lewy F. Paralysis agitans. I. Pathologische anatomie. Handbuch der Neurologie 1912, 920-933. Springer, Berlin. Volume 3.
72. Lollo B., Steele F., Gold L. Beyond antibodies: new affinity reagents to unlock the proteome. Proteomics 2014, 14:638-644.
73. Lord S., Galna B., Rochester L. Moving forward on gait measurement: toward a more refined approach. Mov. Disord. 2013, 28:1534-1543.
74. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
75. Magdalinou N., Lees A.J., Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J.Neurol. Neurosurg. Psychiatry 2014, 85:1065-1075.
76. Malek N., Swallow D., Grosset K.A., Anichtchik O., Spillantini M., Grosset D.G. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Acta Neurol. Scand. 2014, 130:59-72.
77. Mapstone M., Cheema A.K., Fiandaca M.S., Zhong X., Mhyre T.R., MacArthur L.H., Hall W.J., Fisher S.G., Peterson D.R., Haley J.M., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 2014, 20:415-418.
78. Marek K., Jennings D., Tamagnan G., Seibyl J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann. Neurol. 2008, 64(Suppl 2):S111-S121.
79. Marek K., Jennings D., Lasch S., Siderowf A., Tanner C., Simuni T., Coffey C., Kieburtz K., Flagg E., Chowdhury S. The parkinson progression marker initiative (PPMI). Prog. Neurobiol. 2011, 95:629-635. Parkinson Progression Marker Initiative.
80. Marras C., Rochon P., Lang A.E. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch. Neurol. 2002, 59:1724-1728.
81. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
82. Mayeux R., Denaro J., Hemenegildo N., Marder K., Tang M.X., Cote L.J., Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch. Neurol. 1992, 49:492-497.
83. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
84. Mehan M.R., Williams S.A., Siegfried J.M., Bigbee W.L., Weissfeld J.L., Wilson D.O., Pass H.I., Rom W.N., Muley T., Meister M., et al. Validation of a blood protein signature for non-small cell lung cancer. Clin. Proteomics 2014, 11:32.
85. Molinuevo J.L., Blennow K., Dubois B., Engelborghs S., Lewczuk P., Perret-Liaudet A., Teunissen C.E., Parnetti L. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2014, Published online August 20, 2014. 10.1016/j.jalz.2014.03.003.
86. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T.F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H.A., McLean P.J., et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 2008, 213:315-325.
87. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C., Schlossmacher M.G. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230-240.
88. Mollenhauer B., Rochester L., Chen-Plotkin A., Brooks D. What can biomarkers tell us about cognition in Parkinson's disease?. Mov. Disord. 2014, 29:622-633.
89. Molochnikov L., Rabey J.M., Dobronevsky E., Bonucelli U., Ceravolo R., Frosini D., Grünblatt E., Riederer P., Jacob C., Aharon-Peretz J., et al. A molecular signature in blood identifies early Parkinson's disease. Mol. Neurodegener. 2012, 7:26.
90. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., Chung K.A., Kim H., Galasko D.R., Jankovic J., et al. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 2010, 25:2682-2685.
91. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin. N. Am. 2005, 15:869-877. xi-xii.
92. Nair V.S., Pritchard C.C., Tewari M., Ioannidis J.P. Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies. Am. J. Epidemiol. 2014, 180:140-152.
93. National Cancer Institute (2014). What is Proteomics?. http://proteomics.cancer.gov/whatisproteomics.
94. NIH-NINDS (2014). http://www.commondataelements.ninds.nih.gov/PD.aspx.
95. O'Bryant S.E., Gupta V., Henriksen K., Edwards M., Jeromin A., Lista S., Bazenet C., Soares H., Lovestone S., Hampel H., et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement. 2014, STAR-B and BBBIG working groups, Published online September 27, 2014. 10.1016/j.jalz.2014.08.099.
96. Olanow C.W., Kieburtz K., Schapira A.H. Why have we failed to achieve neuroprotection in Parkinson's disease?. Ann. Neurol. 2008, 64(Suppl 2):S101-S110.
97. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N.Engl. J. Med. 2004, 351:2817-2826.
98. Park M.J., Cheon S.M., Bae H.R., Kim S.H., Kim J.W. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J Clin Neurol 2011, 7:215-222.
99. Parkinson J. An essay on the shaking palsy 1817, Sherwood, Neely, and Jones, London.
100. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007, 69:1480-1490. Parkinson Study Group PRECEPT Investigators.
101. Parkinson's Disease Biomarkers Program (2014). https://pdbp.ninds.nih.gov.
102. Parkinson's Progression Markers Initiative (2014). http://www.ppmi-info.org.
103. Parnetti L., Castrioto A., Chiasserini D., Persichetti E., Tambasco N., El-Agnaf O., Calabresi P. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013, 9:131-140.
104. Partin J.F., Mamounas E.P. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. Ann. Surg. Oncol. 2011, 18:3399-3406.
105. Pellecchia M.T., Santangelo G., Picillo M., Pivonello R., Longo K., Pivonello C., Vitale C., Amboni M., De Rosa A., Moccia M., et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J.Neurol. 2013, 260:438-444.
106. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
107. Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
108. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
109. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1300.
110. Pressley J.C., Louis E.D., Tang M.X., Cote L., Cohen P.D., Glied S., Mayeux R. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 2003, 60:87-93.
111. Qiang J.K., Wong Y.C., Siderowf A., Hurtig H.I., Xie S.X., Lee V.M., Trojanowski J.Q., Yearout D., B Leverenz J., Montine T.J., et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann. Neurol. 2013, 74:119-127.
112. Raamsdonk L.M., Teusink B., Broadhurst D., Zhang N., Hayes A., Walsh M.C., Berden J.A., Brindle K.M., Kell D.B., Rowland J.J., et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol. 2001, 19:45-50.
113. Rajput A.H., Rozdilsky B., Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can. J. Neurol. Sci. 1991, 18:275-278.
114. Rascol O., Fitzer-Attas C.J., Hauser R., Jankovic J., Lang A., Langston J.W., Melamed E., Poewe W., Stocchi F., Tolosa E., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011, 10:415-423.
115. Rascol O., Lozano A., Stern M., Poewe W. Milestones in Parkinson's disease therapeutics. Mov. Disord. 2011, 26:1072-1082.
116. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., Dhawan V., Feigin A., Fahn S., Guttman M., et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64:208-215.
117. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
118. Ross G.W., Petrovitch H., Abbott R.D., Tanner C.M., Popper J., Masaki K., Launer L., White L.R. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann. Neurol. 2008, 63:167-173.
119. Ross J.S., Hatzis C., Symmans W.F., Pusztai L., Hortobágyi G.N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13:477-493.
120. Sawyers C.L. The cancer biomarker problem. Nature 2008, 452:548-552.
121. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388-393.
122. Scherzer C.R., Eklund A.C., Morse L.J., Liao Z., Locascio J.J., Fefer D., Schwarzschild M.A., Schlossmacher M.G., Hauser M.A., Vance J.M., et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. USA 2007, 104:955-960.
123. Schmid A.W., Fauvet B., Moniatte M., Lashuel H.A. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell. Proteomics 2013, 12:3543-3558.
124. Schwarzschild M.A., Schwid S.R., Marek K., Watts A., Lang A.E., Oakes D., Shoulson I., Ascherio A., Hyson C., Gorbold E., et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 2008, 65:716-723. Parkinson Study Group PRECEPT Investigators.
125. Schwenk J.M., Lindberg J., Sundberg M., Uhlén M., Nilsson P. Determination of binding specificities in highly multiplexed bead-based assays for antibody proteomics. Mol. Cell. Proteomics 2007, 6:125-132.
126. Seng P., Drancourt M., Gouriet F., La Scola B., Fournier P.E., Rolain J.M., Raoult D. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin. Infect. Dis. 2009, 49:543-551.
127. Shah M., Catafau A.M. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers. J.Nucl. Med. 2014, 55:871-874.
128. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413. Alzheimer's Disease Neuroimaging Initiative.
129. Shehadeh L.A., Yu K., Wang L., Guevara A., Singer C., Vance J., Papapetropoulos S. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PLoS ONE 2010, 5:e9104.
130. Sherer T.B. Biomarkers for Parkinson's disease. Sci. Transl. Med. 2011, 3:79ps14.
131. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
132. Siderowf A., Xie S.X., Hurtig H., Weintraub D., Duda J., Chen-Plotkin A., Shaw L.M., Van Deerlin V., Trojanowski J.Q., Clark C. CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061.
133. Siderowf A., Jennings D., Eberly S., Oakes D., Hawkins K.A., Ascherio A., Stern M.B., Marek K. Impaired olfaction andother prodromal features in the Parkinson At-Risk Syndrome Study. Mov. Disord. 2012, 27:406-412. PARS Investigators.
134. Sierks M.R., Chatterjee G., McGraw C., Kasturirangan S., Schulz P., Prasad S. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 2011, 3:1188-1196.
135. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
136. Solier C., Langen H. Antibody-based proteomics and biomarker research - current status and limitations. Proteomics 2014, 14:774-783.
137. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups ondiagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
138. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. α-synuclein in Lewy bodies. Nature 1997, 388:839-840.
139. Stranger B.E., Stahl E.A., Raj T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 2011, 187:367-383.
140. Suchowersky O., Reich S., Perlmutter J., Zesiewicz T., Gronseth G., Weiner W.J. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:968-975. Quality Standards Subcommittee of the American Academy of Neurology.
141. Svenningsson P., Westman E., Ballard C., Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012, 11:697-707.
142. Swanson C.R., Li K., Unger T.L., Gallagher M.D., Van Deerlin V.M., Agarwal P., Leverenz J., Roberts J., Samii A., Gross R.G., et al. Lower plasma Apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. Mov. Disord. 2014, 10.1002/mds.26022.
143. Tapiola T., Alafuzoff I., Herukka S.K., Parkkinen L., Hartikainen P., Soininen H., Pirttilä T. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009, 66:382-389.
144. Tateno F., Sakakibara R., Kawai T., Kishi M., Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2012, 26:213-216.
145. NINDS boosts research for biomarkers in Parkinson's disease. Lancet Neurol. 2013, 12:217. The Lancet Neurology.
146. Tian Q., Price N.D., Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J.Intern. Med. 2012, 271:111-121.
147. Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa M., Qureshi M.M., Locascio J.J., Schlossmacher M.G., El-Agnaf O.M. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 349:162-166.
148. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
149. Trétiakoff C. Contribution a l'etude l'anatomie pathologique du locus Niger de soemmering: avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson 1919, University of Paris, Paris.
150. Trinh J., Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013, 9:445-454.
151. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
152. Uhl G.R. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov. Disord. 2003, 18(Suppl 7):S71-S80.
153. Vaillancourt D.E., Spraker M.B., Prodoehl J., Abraham I., Corcos D.M., Zhou X.J., Comella C.L., Little D.M. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009, 72:1378-1384.
154. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
155. Vanderstichele H., Bibl M., Engelborghs S., Le Bastard N., Lewczuk P., Molinuevo J.L., Parnetti L., Perret-Liaudet A., Shaw L.M., Teunissen C., et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2012, 8:65-73.
156. Vogeser M., Seger C. A decade of HPLC-MS/MS in the routineclinical laboratory-goals for further developments. Clin. Biochem. 2008, 41:649-662.
157. Volkow N.D., Wang G.J., Fowler J.S., Ding Y.S. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:1410-1415.
158. Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D., Srulijes K., Trojanowski J.Q., Lee V.M., Siderowf A.D., et al. Phosphorylated α-synuclein in Parkinson's disease. Sci. Transl. Med. 2012, 4:21ra20.
159. Wang J., Hoekstra J.G., Zuo C., Cook T.J., Zhang J. Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discov. Today 2013, 18:155-162.
160. Weiner M.W., Veitch D.P., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., Harvey D., Jack C.R., Jagust W., Liu E., et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013, 9:e111-e194. Alzheimer's Disease Neuroimaging Initiative.
161. Weisskopf M.G., O'Reilly E., Chen H., Schwarzschild M.A., Ascherio A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 2007, 166:561-567.
162. Welter D., MacArthur J., Morales J., Burdett T., Hall P., Junkins H., Klemm A., Flicek P., Manolio T., Hindorff L., Parkinson H. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014, 42(Database issue):D1001-D1006.
163. Wimo A., Prince M. World Alzheimer Report 2010: The Global Economic Impact of Dementia 2010, Alzheimer's Disease International, London.
164. Yalow R.S., Berson S.A. Assay of plasma insulin in human subjects by immunological methods. Nature 1959, 184(Suppl 21):1648-1649.
165. Zerhouni E.A. Translational and clinical science-time for a new vision. N.Engl. J. Med. 2005, 353:1621-1623.
166. Zhang J., Sokal I., Peskind E.R., Quinn J.F., Jankovic J., Kenney C., Chung K.A., Millard S.P., Nutt J.G., Montine T.J. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 2008, 129:526-529.